Danaher Corporation (DHR)
$
198.8
-2.66 (-1.34%)
Key metrics
Financial statements
Free cash flow per share
6.8435
Market cap
140.6 Billion
Price to sales ratio
5.9005
Debt to equity
0.3240
Current ratio
1.4334
Income quality
1.6595
Average inventory
2.4 Billion
ROE
0.0747
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Danaher Corporation designs, manufactures, and markets a wide array of professional, medical, industrial, and commercial products and services on a global scale. The company operates through three primary segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides an extensive range of products, including mass spectrometers, flow cytometry solutions, genomics instruments, lab automation systems, centrifugation devices, particle counting and characterization tools, and microscopes. This segment is also engaged in genomics consumables and Gene and Cell Therapy, in addition to offering bioprocess technologies, consumables, and services. Furthermore, it supplies filtration, separation, and purification technologies catering to pharmaceutical and biopharmaceutical companies, as well as food and beverage firms, medical institutions, universities, and various industrial manufacturers. The Diagnostics segment delivers a comprehensive suite of diagnostic solutions, which includes chemistry, immunoassay, microbiology, and automation systems alongside an array of hematology, molecular, acute care, and pathology diagnostics products. This segment also encompasses clinical instruments, reagents, consumables, software, and services that are essential for hospitals, physicians’ offices, reference laboratories, and other critical care environments. Meanwhile, the Environmental & Applied Solutions segment focuses on providing instrumentation, consumables, software, services, and disinfection systems designed to analyze, treat, and manage various types of water across residential, commercial, industrial, and natural resource applications. Moreover, it offers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality management, as well as printing, marking, coding, and traceability applications across consumer, pharmaceutical, and industrial sectors. The company, originally known as Diversified Mortgage Investors, Inc., rebranded as Danaher Corporation in 1984. Established in 1969, the company is headquartered in Washington, D.C. The income before tax ratio is 0.19 reflecting the pre-tax margin. The company reported a substantial revenue of $23,875,000,000.00 reflecting its strong market presence. The EBITDA is $7,276,000,000.00 a key indicator of the company's operational profitability. The company reported an income before tax of $4,646,000,000.00 showcasing its pre-tax profitability. Additionally, the company reported selling, general, and administrative expenses of $7,759,000,000.00 indicating its operational overhead costs. Danaher Corporation’s stock is priced at $201.46 positioning it in the higher-end market. The stock has a high average trading volume of 4,208,906.00 indicating strong liquidity. With a large market capitalization of $142,275,196,000.00 the company is a dominant player. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth.
Is Danaher Corporation (DHR) a good investment?
Investing in Danaher Corporation (DHR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is Danaher Corporation (DHR)'s stock forecast?
Analysts predict Danaher Corporation stock to fluctuate between $171 (low) and $281.70 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Danaher Corporation's market capitalization?
As of 2025-06-27, Danaher Corporation's market cap is $142,275,196,000, based on 715,670,000 outstanding shares.
How does Danaher Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Danaher Corporation has a Lower Market-Cap, indicating a difference in performance.
Does Danaher Corporation pay dividends?
Danaher Corporation pays dividends. The current dividend yield is 0.59%, with a payout of $0.32 per share.
How can I buy Danaher Corporation (DHR) stock?
To buy Danaher Corporation (DHR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DHR. Place an order (Market, Limit, etc.).
What is the best time to invest in Danaher Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Danaher Corporation stock ever split?
Danaher Corporation's last stock split was 141:125 on 2023-10-02.
How did Danaher Corporation perform in the last earnings report?
Revenue: $23,875,000,000 | EPS: $5.33 | Growth: -17.24%.
Where can I find Danaher Corporation's investor relations reports?
Visit https://www.danaher.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Danaher Corporation?
You can explore historical data from here
What is the all-time high and low for Danaher Corporation stock?
All-time high: $333.96 (2021-09-10) | All-time low: $171 (2025-04-09).
What are the key trends affecting Danaher Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?
prnewswire.com
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer.
prnewswire.com
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
seekingalpha.com
The company has achieved returns on equity above 7.8% since 2019. Additionally, it reduced its liabilities-to-assets ratio to 35.72% this quarter, indicating a low risk of bankruptcy. Danaher expects an excellent growth outlook in the upcoming years, due to the significant investment that the biopharma industry has dedicated to developing new medical therapies. Between 2017 and 2024, Danaher invested 25.81% of its revenues to expand its operations, which has contributed to the growth rate of its revenues.
prnewswire.com
WASHINGTON , June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour.
zacks.com
Investors with an interest in Medical Services stocks have likely encountered both CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
zacks.com
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
prnewswire.com
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid diagnostics research, development and commercialization Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalities WASHINGTON , May 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced today the launch of a partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize novel diagnostic tools and tests intended to help clinicians better determine which patients would most benefit from precision medicine treatments. "Precision medicines are more targeted than standard therapies and thus require precision diagnostics to determine which patients are most likely to benefit," said Julie Sawyer Montgomery, Danaher Executive Vice President.
zacks.com
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
See all news
